



General Assembly

**Amendment**

February Session, 2024

LCO No. 4018



Offered by:

SEN. MARONEY, 14<sup>th</sup> Dist.  
REP. D'AGOSTINO, 91<sup>st</sup> Dist.  
SEN. CICARELLA, 34<sup>th</sup> Dist.  
REP. RUTIGLIANO, 123<sup>rd</sup> Dist.

To: Subst. Senate Bill No. 133

File No. 89

Cal. No. 78

**"AN ACT CONCERNING REGULATION OF PRESCRIPTION DRUGS  
AND RELATED PROFESSIONS."**

1 Strike everything after the enacting clause and substitute the  
2 following in lieu thereof:

3 "Section 1. Section 20-571 of the 2024 supplement to the general  
4 statutes is repealed and the following is substituted in lieu thereof  
5 (*Effective October 1, 2024*):

6 As used in this chapter and sections 2 to 4, inclusive, of this act, unless  
7 the context otherwise requires:

8 (1) "Administer" or "administration" means the direct application of  
9 a drug or device to the body of a patient or research subject by injection,  
10 inhalation, ingestion or any other means;

11 (2) "Advanced pharmacy technician" means a pharmacy technician

12 who receives a designation from the department and is qualified in  
13 accordance with section 2 of this act;

14 [(2)] (3) "Automated prescription dispensing machine" means a  
15 device and associated software operated by a pharmacy or a pharmacy  
16 that is registered as a nonresident pharmacy pursuant to section 20-627,  
17 in a nursing home or skilled nursing facility licensed pursuant to  
18 sections 19a-490 and 19a-491, that packages and labels patient-specific  
19 medication or multiple medications for the purposes of administration  
20 by a registered nurse or a licensed practical nurse based on a  
21 prescription that has completed [final] order entry verification  
22 performed by a [licensed] pharmacist;

23 [(3)] (4) "Care-giving institution" means an institution that provides  
24 medical services and is licensed, operated, certified or approved by the  
25 Commissioner of Public Health, the Commissioner of Developmental  
26 Services or the Commissioner of Mental Health and Addiction Services;

27 (5) "Clerk" means an individual who is: (A) Registered with the  
28 department, in accordance with section 3 of this act, to work in the area  
29 of a pharmacy or institutional pharmacy where controlled substances or  
30 other legend drugs are dispensed by, or under the supervision of, a  
31 pharmacist; (B) not employed or contracted by a pharmacy or  
32 institutional pharmacy solely to deliver dispensed drugs to patients off  
33 the premises of the pharmacy or institutional pharmacy; and (C) not  
34 involved in order entry, the dispensing process or preparing a  
35 prescription for final verification;

36 [(4)] (6) "Commission" means the Commission of Pharmacy  
37 appointed under the provisions of section 20-572;

38 [(5)] (7) "Commissioner" means the Commissioner of Consumer  
39 Protection;

40 (8) "Compatible drugs" means multiple drugs that are not adversely  
41 impacted, whether chemically or physically, in constitution or quality  
42 by one another;

43 (9) "Compliance packaging" means packaging that: (A) Is prepared at  
44 a pharmacy to assist a patient in administering solid oral dosage forms  
45 of one or more drugs that have been prescribed for the patient; (B)  
46 divides the patient's drugs into a series of compartments or containers  
47 within one package according to (i) the directions for use, and (ii) the  
48 day and time such drugs are to be administered; and (C) is reusable or  
49 nonreusable;

50 [(6)] (10) "Compound" means to combine, mix or put together two or  
51 more ingredients pursuant to a prescription and includes the  
52 preparation of drugs or devices in anticipation of prescriptions based on  
53 routine, regularly-observed prescribing patterns;

54 [(7)] (11) "Correctional or juvenile training institution" means a  
55 facility for the detention or incarceration of persons convicted or  
56 accused of crimes or offenses or for training of delinquent juveniles,  
57 including those state facilities under the jurisdiction of the  
58 Commissioner of Correction, training schools for delinquent juveniles  
59 and any other facilities operated by the state or municipalities for such  
60 detention, incarceration or training;

61 [(8)] (12) "Device" means instruments, apparatuses and contrivances,  
62 including their components, parts and accessories, intended: (A) For use  
63 in the diagnosis, cure, mitigation, treatment or prevention of disease in  
64 humans or other animals; or (B) to affect the structure or any function of  
65 the body of humans or other animals, but does not mean contact lenses;

66 [(9)] (13) "Department" means the Department of Consumer  
67 Protection;

68 [(10)] (14) "Deprescribing" means the systematic process of  
69 identifying and discontinuing drugs in instances in which existing or  
70 potential harms outweigh existing or potential benefits within the  
71 context of an individual patient's care goals, current level of functioning,  
72 life expectancy, values and preferences;

73 (15) "Direct supervision" means the supervision of pharmacy

74 personnel, including, but not limited to, pharmacy interns, pharmacy  
75 technicians and advanced pharmacy technicians, by a pharmacist who:  
76 (A) Is physically present on the premises of the pharmacy or  
77 institutional pharmacy while (i) routine drug dispensing functions are  
78 being performed on such premises, and (ii) the pharmacy personnel  
79 who are under such pharmacist's supervision are physically present on  
80 such premises; and (B) conducts in-process and final performance  
81 checks;

82 [(11)] (16) "Dispense" means those acts of processing a drug or device  
83 for delivery or for administration for a patient pursuant to a prescription  
84 consisting of: (A) Comparing the directions on the label with the  
85 directions on the prescription to determine accuracy; (B) the selection of  
86 the drug or device from stock to fill the prescription; (C) the counting,  
87 measuring, compounding or preparation of the drug or device; (D) the  
88 placing of the drug or device in the proper container; (E) the affixing of  
89 the label to the container; and (F) the addition to a written prescription  
90 of any required notations. "Dispense" does not include the acts of  
91 delivering a drug or device to a patient or of administering the drug or  
92 device to the patient;

93 [(12)] (17) "Dispensing outpatient facility" means a facility operated  
94 by a [corporation] business entity or municipality which provides  
95 medical services to patients on an outpatient basis and which maintains  
96 stocks of drugs for dispensing of drugs on a regular basis to patients for  
97 use off the premises;

98 [(13)] (18) "Drug" means: (A) An article recognized in the official  
99 United States Pharmacopoeia, official Homeopathic Pharmacopoeia of  
100 the United States or official National Formulary, or any supplement to  
101 any of them; (B) an article intended for use in the diagnosis, cure,  
102 mitigation, treatment or prevention of disease in humans or other  
103 animals; (C) an article, other than food, intended to affect the structure  
104 or any function of the body of humans or any other animal; and (D) an  
105 article intended for use as a component of any article specified in this  
106 subdivision, but does not include a device;

107 (19) "Final verification" means the last review that: (A) Is conducted  
108 to complete the dispensing process by verifying that the product to be  
109 dispensed conforms to the product ordered or prescribed by the  
110 prescribing practitioner; and (B) includes, at a minimum, comparing, for  
111 accuracy, the original prescription, the contents of the prescription label  
112 and the contents of the prescription container;

113 [(14)] (20) "Health care institution" means institution, as defined in  
114 section 19a-490;

115 [(15)] (21) "Health care institutional pharmacy" means an institutional  
116 pharmacy located within a health care institution;

117 [(16)] (22) "Institutional pharmacy" means that area within a care-  
118 giving institution or within a correctional or juvenile training  
119 institution, commonly known as the pharmacy, that is under the direct  
120 charge of a pharmacist and in which drugs are stored and dispensed;

121 [(17)] (23) "Legend device" means a device that is required by  
122 applicable federal or state law to be dispensed pursuant only to a  
123 prescription or is restricted to use by prescribing practitioners only or  
124 that, under federal law, is required to bear either of the following  
125 legends: (A) "RX ONLY" IN ACCORDANCE WITH GUIDELINES  
126 ESTABLISHED IN THE FEDERAL FOOD, DRUG AND COSMETIC  
127 ACT; or (B) "CAUTION: FEDERAL LAW RESTRICTS THIS DEVICE  
128 FOR USE BY OR ON THE ORDER OF A LICENSED VETERINARIAN.";

129 [(18)] (24) "Legend drug" means a drug that is required by any  
130 applicable federal or state law to be dispensed pursuant only to a  
131 prescription or is restricted to use by prescribing practitioners only, or  
132 means a drug that, under federal law, is required to bear either of the  
133 following legends: (A) "RX ONLY" IN ACCORDANCE WITH  
134 GUIDELINES ESTABLISHED IN THE FEDERAL FOOD, DRUG AND  
135 COSMETIC ACT; or (B) "CAUTION: FEDERAL LAW RESTRICTS THIS  
136 DRUG FOR USE BY OR ON THE ORDER OF A LICENSED  
137 VETERINARIAN.";

138        [(19)] (25) "Medical device and oxygen provider" means a person who  
139 distributes devices or oxygen pursuant to a medical order or  
140 prescription, except if such person already maintains an active  
141 pharmacy license;

142        [(20)] (26) "Medication reconciliation" means a process of comparing  
143 the medications a patient is taking and should be taking with newly  
144 ordered medications: (A) For the purpose of addressing duplications,  
145 omissions and interactions and the need to continue current  
146 medications; and (B) by looking at information such as the medication  
147 name, dose, frequency, route of administration and purpose;

148        [(21)] (27) "Nonlegend device" means a device that is not a legend  
149 device;

150        [(22)] (28) "Nonlegend drug" means a drug that is not a legend drug;

151        [(23)] (29) "Nonresident pharmacy" has the same meaning as  
152 provided in section 20-627;

153        (30) "Order entry" means the process by which prescription data is  
154 entered into an electronic data processing system used by a pharmacy  
155 to record dispensed products, which prescription data shall include, but  
156 need not be limited to: (A) Patient demographic data; (B) drug name and  
157 strength; (C) drug quantity; (D) directions for use; and (E) the number  
158 of authorized refills, including, but not limited to, any use of "PRN" or  
159 "ad lib" in lieu of a specific number of authorized refills;

160        (31) "Patient" means a human or other animal who receives any  
161 health care service provided by a health care provider, including, but  
162 not limited to, a pharmacist, for: (A) The purpose of curing, diagnosing,  
163 mitigating, palliating, preventing, screening for or treating a past,  
164 current or future medical condition; or (B) any research-related purpose;

165        [(24)] (32) "Person" means an individual, corporation, business trust,  
166 estate trust, partnership, association, joint venture or any other legal or  
167 commercial entity;

168 [(25)] (33) "Pharmacist" means an individual who is licensed to  
169 practice pharmacy under the provisions of section 20-590, 20-591, 20-592  
170 or 20-593, and who is thereby recognized as a health care provider by  
171 the state of Connecticut;

172 [(26)] (34) "Pharmacy" means a place of business where drugs and  
173 devices may be sold at retail and for which a pharmacy license has been  
174 issued to an applicant under the provisions of section 20-594;

175 [(27)] (35) "Pharmacy intern" means an individual registered under  
176 the provisions of section 20-598;

177 [(28)] (36) "Pharmacy technician" means an individual who is  
178 registered with the department and qualified in accordance with section  
179 20-598a, as amended by this act;

180 [(29)] (37) "Polypharmacy" means the use of multiple drugs by a  
181 patient, including any medication that is inappropriate or not medically  
182 necessary, such as those not indicated, not effective or constituting a  
183 therapeutic duplication;

184 [(30)] (38) "Practice of pharmacy" or "to practice pharmacy" means the  
185 sum total of knowledge, understanding, judgments, procedures,  
186 securities, controls and ethics used by a pharmacist to assure optimal  
187 safety and accuracy in the distributing, dispensing and use of drugs and  
188 devices;

189 [(31)] (39) "Prescribing practitioner" means an individual licensed by  
190 the state of Connecticut, any other state of the United States, the District  
191 of Columbia, the Commonwealth of Puerto Rico or any territory or  
192 insular possession subject to the jurisdiction of the United States who is  
193 authorized to issue a prescription within the scope of the individual's  
194 practice;

195 [(32)] (40) "Prescription" means a lawful order of a prescribing  
196 practitioner transmitted either orally, in writing or by electronic means  
197 for a drug or device for a specific patient;

198 (41) "Redispense" means to reprocess any drug: (A) That is prescribed  
199 to a patient, was previously dispensed in compliance packaging and has  
200 been returned to the dispensing pharmacy due to a change in the  
201 patient's prescription or prescriptions; (B) by comparing the directions  
202 on the prescription label with the directions on the prescription to  
203 ensure accuracy; (C) by selecting such drug from the returned  
204 compliance packaging or from stock to fill a current prescription for  
205 such drug; (D) by counting such drug and placing such drug in the  
206 proper container or compliance packaging compartment for return to  
207 the patient; and (E) by affixing to the container or compliance packaging  
208 a label containing (i) the prescription information set forth in section 20-  
209 617 and required under section 4 of this act, and (ii) any additional  
210 notations required due to the prescribing practitioner's directions;

211 [(33)] (42) "Sale" includes barter, exchange or gift or offer and each  
212 such transaction made by a person whether as principal proprietor,  
213 agent, servant or employee;

214 [(34)] (43) "Substitute" means to dispense without the prescribing  
215 practitioner's express authorization a different drug product than the  
216 drug product prescribed;

217 [(35)] (44) "Third-party logistics provider" means a person who  
218 distributes drugs, devices or cosmetics while taking possession of the  
219 drugs, devices or cosmetics but who does not take title of the drugs,  
220 devices or cosmetics;

221 [(36)] (45) "Virtual manufacturer" means a person who engages in the  
222 manufacture of drugs, devices or cosmetics for which such person: (A)  
223 Owens the new drug application or abbreviated new drug application  
224 number, if a prescription drug; (B) owns the unique device identification  
225 number, as available, for a prescription device; (C) contracts with a  
226 contract manufacturing organization for the physical manufacture of  
227 the drugs, devices or cosmetics; (D) is not involved in the physical  
228 manufacture of the drugs, devices or cosmetics; and (E) at no time takes  
229 physical possession of or stores the drugs, devices or cosmetics; and



230 [(37)] (46) "Virtual wholesale distributor" means a person who  
231 facilitates or brokers the transfer of drugs, devices or cosmetics without  
232 taking physical possession of the drugs, devices or cosmetics.

233 Sec. 2. (NEW) (*Effective October 1, 2024*) (a) (1) No individual may  
234 perform the duties of an advanced pharmacy technician in this state,  
235 including, but not limited to, dispensing or redispensing to patients  
236 compatible drugs in compliance packaging under section 4 of this act,  
237 unless such individual is a pharmacy technician who has applied for  
238 and received an advanced pharmacy technician designation in  
239 accordance with the provisions of this section.

240 (2) Each advanced pharmacy technician designation issued under  
241 this section shall be issued in a form and manner prescribed by the  
242 commissioner, shall be valid for one year and may be renewed for  
243 successive one-year periods upon application and payment of the  
244 renewal fee required in section 20-601 of the general statutes, as  
245 amended by this act.

246 (b) The department shall issue an advanced pharmacy technician  
247 designation to a pharmacy technician who:

248 (1) Submits to the department, in a form and manner prescribed by  
249 the commissioner, (A) a completed application for designation as an  
250 advanced pharmacy technician, and (B) the application fee required in  
251 section 20-601 of the general statutes, as amended by this act;

252 (2) Is actively registered and qualified as a pharmacy technician in  
253 accordance with section 20-598a of the general statutes, as amended by  
254 this act;

255 (3) Was continuously registered as a pharmacy technician in  
256 accordance with section 20-598a of the general statutes, as amended by  
257 this act, for the three-year period immediately preceding the date on  
258 which such pharmacy technician applies for an advanced pharmacy  
259 technician designation under this section;

260 (4) Continuously held a certification from the Pharmacy Technician  
261 Certification Board, or any other equivalent pharmacy technician  
262 certification program approved by the department, for the three-year  
263 period immediately preceding the date on which such pharmacy  
264 technician applies for an advanced pharmacy technician designation  
265 under this section, and maintains such certification in good standing;

266 (5) Successfully completed (A) an educational course, during the one-  
267 year period immediately preceding the date on which such pharmacy  
268 technician applies for an initial advanced pharmacy technician  
269 designation under this section, that (i) is accredited by the Accreditation  
270 Council for Pharmacy Education or another appropriate national  
271 accrediting body, or (ii) the commissioner, in the commissioner's  
272 discretion, deems equivalent to an educational course accredited as set  
273 forth in subparagraph (A)(i) of this subdivision, and (B) a competency  
274 assessment performed by a pharmacist in accordance with requirements  
275 established by the commissioner in regulations adopted pursuant to  
276 subsection (e) of this section;

277 (6) Is employed by a pharmacy or institutional pharmacy that  
278 satisfies the requirements established in subsection (d) of this section;  
279 and

280 (7) (A) Works under the direct supervision of a pharmacist who  
281 satisfies the requirements established in subdivision (1) of subsection (c)  
282 of this section; or

283 (B) Is supervised (i) in the manner set forth in section 20-609a of the  
284 general statutes, or (ii) in any manner approved by the commissioner or  
285 commission.

286 (c) (1) The pharmacist who directly supervises an advanced  
287 pharmacy technician as required under subdivision (7) of subsection (b)  
288 of this section shall perform all applicable drug utilization reviews,  
289 including, but not limited to, all prospective and retrospective drug  
290 utilization reviews required under state or federal law, to ensure  
291 appropriate decision-making concerning drugs and promote positive

292 patient outcomes.

293 (2) (A) The pharmacist who directly supervises an advanced  
294 pharmacy technician may delegate to the advanced pharmacy  
295 technician:

296 (i) The pharmacist's authority to perform final verifications, provided  
297 the pharmacy or institutional pharmacy that employs such advanced  
298 pharmacy technician satisfies the requirements established in  
299 subsection (d) of this section;

300 (ii) The pharmacist's authority to administer vaccines in accordance  
301 with the provisions of section 20-633 of the general statutes, as amended  
302 by this act, and the regulations adopted pursuant to subsection (d) of  
303 said section; and

304 (iii) The pharmacist's authority to administer COVID-19-related tests,  
305 influenza-related tests and HIV-related tests in accordance with the  
306 provisions of section 20-633f of the general statutes, as amended by this  
307 act, and the regulations adopted pursuant to subsection (g) of said  
308 section.

309 (B) No pharmacist who makes any delegation to an advanced  
310 pharmacy technician under subparagraph (A) of this subdivision shall  
311 delegate to the advanced pharmacy technician any discretionary  
312 decision-making authority concerning the propriety of any drug in  
313 relation to a patient's medical condition or treatment plan.

314 (d) (1) The pharmacy or institutional pharmacy that employs an  
315 advanced pharmacy technician:

316 (A) Shall use bar code technology, or another technology approved  
317 by the department, to assist in dispensing drugs and confirm accuracy  
318 in dispensing; and

319 (B) Shall not permit the ratio of advanced pharmacy technicians to  
320 pharmacists physically present in the pharmacy premises or  
321 institutional pharmacy to exceed one advanced pharmacy technician to

322 one pharmacist providing direct supervision, except such pharmacy or  
323 institutional pharmacy may deviate from such ratio if such deviation is  
324 authorized by the commissioner or commission, including, but not  
325 limited to, in any regulation adopted by the commissioner pursuant to  
326 subsection (e) of this section. The commissioner or commission shall not  
327 provide for a ratio of pharmacy technicians to supervising pharmacists  
328 that is lower than three-to-one, and no advanced pharmacy technician  
329 shall be counted toward such ratio.

330 (2) If a pharmacy employs an advanced pharmacy technician, the  
331 pharmacy shall, in addition to satisfying the requirements set forth in  
332 subdivision (1) of this subsection, not allow the advanced pharmacy  
333 technician to perform any final verification under subparagraph (A) of  
334 subdivision (2) of subsection (c) of this section unless such advanced  
335 pharmacy technician, in performing such final verification, uses a  
336 technology that includes images of each drug that such advanced  
337 pharmacy technician reviews in performing such final verification.

338 (3) If an institutional pharmacy employs an advanced pharmacy  
339 technician, the institutional pharmacy shall, in addition to satisfying the  
340 requirements set forth in subdivision (1) of this subsection, not allow the  
341 advanced pharmacy technician to perform any final verification under  
342 subparagraph (A) of subdivision (2) of subsection (c) of this section  
343 unless such institutional pharmacy uses bar code scanning, or another  
344 technology or process approved by the department, at the point of  
345 administration to confirm accuracy in dispensing.

346 (e) The commissioner shall adopt regulations, in accordance with the  
347 provisions of chapter 54 of the general statutes, to implement the  
348 provisions of this section. Such regulations shall, at a minimum,  
349 establish requirements for performance of the competency assessment  
350 required under subparagraph (B) of subdivision (5) of subsection (b) of  
351 this section.

352 Sec. 3. (NEW) (*Effective October 1, 2024*) (a) Except as otherwise  
353 provided in chapter 400j of the general statutes, no individual shall be

354 physically present, and perform any work, in any area of a pharmacy or  
355 institutional pharmacy where controlled substances or other legend  
356 drugs are dispensed by, or under the supervision of, a pharmacist unless  
357 such individual is registered with the department in accordance with  
358 the provisions of this section. For the purposes of this section, an  
359 institutional pharmacy shall not be deemed to include any patient care  
360 area or automated prescription dispensing machine that is located  
361 outside of the area commonly known as the pharmacy.

362 (b) (1) The department shall register as a clerk any individual who  
363 submits to the department, in a form and manner prescribed by the  
364 commissioner, (A) a completed application for registration as a clerk,  
365 and (B) the application fee required in section 20-601 of the general  
366 statutes, as amended by this act.

367 (2) Each clerk registration issued under this section shall be issued in  
368 a form and manner prescribed by the commissioner, shall be valid for  
369 two years and may be renewed for successive two-year periods upon  
370 application and payment of the renewal fee required in section 20-601  
371 of the general statutes, as amended by this act.

372 (3) The department shall not refuse to issue any clerk registration  
373 under this section, or refuse to renew any clerk registration issued under  
374 this section, because the applicant for such registration or renewal has  
375 been convicted of a felony, unless such refusal is rendered in accordance  
376 with the provisions of section 46a-80 of the general statutes.

377 (c) A clerk may, under the direct supervision of a pharmacist, (1)  
378 handle dispensed drugs and deliver such drugs to patients, (2) collect  
379 patient demographic information, (3) collect a prescription number for  
380 the purposes of a refill, (4) deliver a drug to an automated prescription  
381 dispensing machine or other care-giving area within a care-giving  
382 institution or within a correctional or juvenile training institution, (5)  
383 perform the duties of a cashier, including, but not limited to, receiving  
384 payment for dispensed drugs, (6) conduct inventory management, (7)  
385 return to stock any product used to fill a prescription but not sold to a

386 patient, and (8) perform any other duties set forth in regulations  
387 adopted by the commissioner pursuant to subsection (e) of this section.

388 (d) No clerk shall (1) review any drug to determine whether such  
389 drug is an appropriate treatment, (2) verify the accuracy of the  
390 prescription data entered into an electronic data processing system used  
391 by a pharmacy, an original prescription, the contents of a prescription  
392 label or the contents of a prescription container, (3) perform any task  
393 that requires any professional pharmaceutical judgment, or (4)  
394 participate in order entry.

395 (e) The commissioner may adopt regulations, in accordance with the  
396 provisions of chapter 54 of the general statutes, to implement the  
397 provisions of this section, including, but not limited to, regulations (1)  
398 establishing (A) additional requirements for registration as a clerk, and  
399 (B) ratios of clerks to pharmacists in pharmacies and institutional  
400 pharmacies, and (2) concerning (A) the scope of clerks' authority, and  
401 (B) the duties and performance of clerks.

402 Sec. 4. (NEW) (*Effective October 1, 2024*) (a) (1) A pharmacist or  
403 advanced pharmacy technician may, at the request of a patient, the  
404 patient's representative or the patient's prescribing practitioner,  
405 dispense to the patient compatible drugs in compliance packaging.

406 (2) (A) If a patient's prescribing practitioner modifies the patient's  
407 prescription or prescriptions by, among other things, issuing any new  
408 prescription or discontinuing or deprescribing any drug that was  
409 previously dispensed to the patient in compliance packaging, the  
410 pharmacy that first dispensed such previously dispensed drug in such  
411 compliance packaging may, at the request of such patient,  
412 representative or prescribing practitioner and if such pharmacy  
413 documents such modification in writing, (i) accept such compliance  
414 packaging from such patient or representative, (ii) receive and remove  
415 any drugs from such returned compliance packaging and redispense  
416 such drugs to such patient, and (iii) dispense any newly prescribed and  
417 compatible drugs in such returned compliance packaging.

418 (B) Any pharmacy that accepts any compliance packaging returned  
419 under this subdivision shall do so exclusively to (i) dispense to the  
420 patient any compatible drugs that are newly prescribed to such patient,  
421 and (ii) redispense to the patient any returned drugs contained in such  
422 returned compliance packaging in the same quantities that were  
423 contained in such returned compliance packaging when such pharmacy  
424 accepted such returned compliance packaging.

425 (C) Each pharmacy that redispenses any drug contained in any  
426 compliance packaging returned under this subdivision shall redispense  
427 such drug to the patient in (i) compliance packaging that exclusively  
428 contains drugs currently prescribed to such patient, or (ii) a separate  
429 container that is labeled in accordance with the provisions of section 20-  
430 617 of the general statutes and subparagraph (D) of this subdivision.

431 (D) If a pharmacy accepts any compliance packaging returned under  
432 this subdivision and such returned compliance packaging contains one  
433 or more drugs that have been deprescribed, discontinued or have  
434 otherwise been deemed to be inappropriate for inclusion in compliance  
435 packaging, as determined by the patient's prescribing practitioner or a  
436 pharmacist, the pharmacy shall redispense such drugs to the patient in  
437 one or more separate containers, each of which shall (i) include not more  
438 than one drug type or dosage, and (ii) bear a label that includes the  
439 patient's name, the original prescription serial number or serial  
440 numbers, the drug name or names, the dosage form or forms, the  
441 quantity or quantities redispensed and instructions for use or disposal,  
442 as applicable, which instructions shall disclose, at a minimum, (I) the  
443 procedures for any lawfully available means of destroying such drug or  
444 drugs at home, and (II) the nearest location where such drug or drugs  
445 may be deposited for destruction, including, but not limited to, the  
446 nearest retail location allowed to accept such drug or drugs under the  
447 regulations adopted pursuant to section 20-576a of the general statutes.

448 (E) No pharmacy, pharmacist, pharmacy intern or advanced  
449 pharmacy technician shall return to a pharmacy's general inventory or  
450 regular stock any returned drug that was previously contained in any

451 compliance packaging returned under this subdivision, unless  
452 accepting such drug for return to the pharmacy's general inventory or  
453 regular stock is otherwise permitted or required by law.

454 (b) Compliance packaging shall:

455 (1) Exclusively contain (A) individual compartments that are tamper-  
456 evident, and (B) drugs that (i) are currently prescribed to a single patient  
457 pursuant to an order or prescription by the patient's prescribing  
458 practitioner, and (ii) dispensed or redispensed to a single patient by a  
459 pharmacist or an advanced pharmacy technician;

460 (2) Be labeled or relabeled by a pharmacist in accordance with the  
461 provisions of section 20-617 of the general statutes, except if the  
462 compliance packaging contains an opioid drug, as defined in section 20-  
463 14o of the general statutes, only one sticker or label shall be affixed to  
464 such compliance packaging pursuant to section 20-636 of the general  
465 statutes and not to each individual compartment contained in such  
466 compliance packaging;

467 (3) Be child-resistant unless the pharmacy provides to the patient, and  
468 the patient acknowledges and returns to the pharmacy, a waiver  
469 explaining that the drugs contained in the compliance packaging are not  
470 in a child-resistant container;

471 (4) Identify, on each individual compartment, the name and strength  
472 of the drug or drugs contained in such compartment;

473 (5) Not contain more than a ninety-day supply of any drug, as  
474 prescribed, except as otherwise provided in any applicable state or  
475 federal law; and

476 (6) Be compliant with all applicable provisions of the United States  
477 Pharmacopeia, as amended from time to time.

478 (c) (1) Except as provided in subdivision (2) of this subsection,  
479 compliance packaging may contain multiple drugs prescribed to the  
480 same patient. An individual compartment of compliance packaging



481 may contain multiple prescribed drugs, provided:

482 (A) A pharmacist has determined that all drugs contained in such  
483 compartment are compatible drugs;

484 (B) All drugs contained in such compartment are subject to the same  
485 instructions concerning time of administration; and

486 (C) No drug contained in such compartment has instructions for use  
487 that permit such drug to be used on an as needed basis.

488 (2) No controlled substance shall be contained in any compliance  
489 packaging that contains any other drug, unless such other drug is a  
490 controlled substance of the same drug type prescribed at a different  
491 dose.

492 (d) A pharmacy that provides compliance packaging services shall:

493 (1) Maintain an area dedicated to the preparation of drugs that are to  
494 be dispensed or redispensed in compliance packaging, which area shall  
495 include all equipment necessary to:

496 (A) Ensure that all compliance packaging is accurately prepared; and

497 (B) Prevent any contamination of such drugs;

498 (2) Maintain standard operating procedures:

499 (A) For the use of compliance packaging and associated equipment,  
500 which procedures shall include, at a minimum, provisions concerning  
501 (i) inspections of compliance packaging integrity, (ii) cleaning, (iii)  
502 labeling, (iv) dispensing and redispensing, (v) proper hand hygiene, (vi)  
503 quarantine, and (vii) handling of dispensed drugs that are removed  
504 from compliance packaging and redispensed to patients in the manner  
505 set forth in subdivision (2) of subsection (a) of this section; and

506 (B) That specify which drugs (i) are not compatible drugs, (ii) are  
507 suitable to be dispensed or redispensed in compliance packaging, or (iii)  
508 require special consideration to be dispensed or redispensed in

509 compliance packaging; and

510 (3) Maintain the following records:

511 (A) A record of all drugs that the pharmacy dispenses to a patient in  
512 compliance packaging, which record shall include at least the following  
513 for each such drug:

514 (i) The patient's name and address;

515 (ii) The identification number, if any, for the compliance packaging  
516 in which such pharmacy dispensed such drug, the date such compliance  
517 packaging was prepared, the initials of the individual who prepared  
518 such compliance packaging and the initials of the individual who  
519 performed a final verification for such compliance packaging;

520 (iii) The name, strength, lot number and national drug code number  
521 for such drug;

522 (iv) The serial number of the prescription for such drug; and

523 (v) A visual description of such drug;

524 (B) A record of all items of compliance packaging that the pharmacy  
525 accepts from a patient for return and redispensing to the patient in the  
526 manner set forth in subdivision (2) of subsection (a) of this section,  
527 which record shall include at least the following for each such item of  
528 compliance packaging:

529 (i) The patient's name and address;

530 (ii) The identification number, if any, for such item of compliance  
531 packaging;

532 (iii) The date on which such pharmacy accepted such item of  
533 compliance packaging for return and redispensing in such manner;

534 (iv) The name of the pharmacist or pharmacy technician who  
535 documented the return of such item of compliance packaging; and

536 (v) The name, formulation and quantity of each drug contained in  
537 such item of compliance packaging when such pharmacy accepted such  
538 item of compliance packaging for return and redispensing in such  
539 manner, including, but not limited to, the name, formulation and  
540 quantity of each such drug (I) that the patient's prescribing practitioner  
541 has deprescribed, or (II) for which the patient's prescribing practitioner  
542 has discontinued the prescription;

543 (C) A record of all items of compliance packaging in which the  
544 pharmacy redispenses any drug to a patient in the manner set forth in  
545 subdivision (2) of subsection (a) of this section, which record shall  
546 include at least the following for each such item of compliance  
547 packaging:

548 (i) The patient's name and address;

549 (ii) The identification number, if any, for such item of compliance  
550 packaging;

551 (iii) The date such item of compliance packaging was prepared for  
552 redispensing in such manner;

553 (iv) The serial number of the prescription for each drug redispensed  
554 in such item of compliance packaging in such manner;

555 (v) The name, formulation and quantity of each drug redispensed in  
556 such item of compliance packaging in such manner;

557 (vi) The name or initials of the redispensing pharmacist;

558 (vii) The initials of the individual who prepared such item of  
559 compliance packaging for redispensing in such manner; and

560 (viii) The initials of the individual who performed a final verification  
561 for such item of compliance packaging for redispensing in such manner;  
562 and

563 (D) A record of all drugs that the pharmacy redispenses to a patient

564 in any container, other than compliance packaging, in the manner set  
565 forth in subdivision (2) of subsection (a) of this section, which record  
566 shall include at least the following for each such drug:

567 (i) The patient's name and address;

568 (ii) The date such drug was prepared for redispensing in such  
569 container in such manner;

570 (iii) The serial number of the prescription for such drug;

571 (iv) The name and formulation of such drug and the quantity of such  
572 drug that was redispensed in such container in such manner; and

573 (v) The name or initials of the redispensing pharmacist.

574 (e) Each pharmacy shall maintain all records that such pharmacy is  
575 required to maintain pursuant to this section for a period of at least three  
576 years. Not later than forty-eight hours after the department requests that  
577 a pharmacy disclose a copy of any record the pharmacy is required to  
578 maintain pursuant to this section, such pharmacy shall disclose such  
579 copy to the department in electronic form or, if such pharmacy is unable  
580 to disclose such copy in electronic form, in paper form.

581 (f) The commissioner may adopt regulations, in accordance with the  
582 provisions of chapter 54 of the general statutes, to implement the  
583 provisions of this section.

584 Sec. 5. Subsection (a) of section 20-579 of the general statutes is  
585 repealed and the following is substituted in lieu thereof (*Effective October*  
586 *1, 2024*):

587 (a) The commission may refuse to authorize the issuance of a  
588 temporary permit to practice pharmacy, may refuse to authorize the  
589 issuance or renewal of a license to practice pharmacy, a license to  
590 operate a pharmacy or a registration of a pharmacy intern or pharmacy  
591 technician, and may revoke, suspend or place conditions on a license or  
592 temporary permit to practice pharmacy, a license to operate a pharmacy,

593 or a registration of a pharmacy intern or a pharmacy technician, and  
594 may assess a civil penalty of up to one thousand dollars per violation of  
595 any provision of this chapter or take other action permitted in  
596 subdivision (7) of section 21a-7 if the applicant or holder of the license,  
597 temporary permit or registration: (1) Has violated a statute or regulation  
598 relating to drugs, devices or the practice of pharmacy of this state, any  
599 state of the United States, the United States, the District of Columbia, the  
600 Commonwealth of Puerto Rico, any territory or insular possession  
601 subject to the jurisdiction of the United States or a foreign jurisdiction;  
602 (2) has been convicted of violating any criminal statute relating to drugs,  
603 devices or the practice of pharmacy of this state, any state of the United  
604 States, the United States, the District of Columbia, the Commonwealth  
605 of Puerto Rico, any territory or insular possession subject to the  
606 jurisdiction of the United States or a foreign jurisdiction; (3) has been  
607 disciplined by, or is the subject of pending disciplinary action or an  
608 unresolved complaint before, the duly authorized pharmacy  
609 disciplinary agency of any state of the United States, the United States,  
610 the District of Columbia, the Commonwealth of Puerto Rico, any  
611 territory or insular possession subject to the jurisdiction of the United  
612 States or a foreign jurisdiction; (4) has been refused a license or  
613 registration or renewal of a license or registration by any state of the  
614 United States, the United States, the District of Columbia, the  
615 Commonwealth of Puerto Rico, any territory or insular possession  
616 subject to the jurisdiction of the United States or a foreign jurisdiction  
617 based on grounds that are similar to grounds on which Connecticut  
618 could refuse to issue or renew such a license or registration; (5) has  
619 illegally possessed, diverted, sold or dispensed drugs or devices; (6)  
620 abuses or excessively uses drugs, including alcohol; (7) has made false,  
621 misleading or deceptive representations to the public or the  
622 commission; (8) has maintained exclusive telephone lines to, has  
623 maintained exclusive electronic communication with, or has exclusive  
624 access to computers located in offices of prescribing practitioners,  
625 nursing homes, clinics, hospitals or other health care facilities; (9) has  
626 substituted drugs or devices except as permitted in section 20-619; (10)  
627 has accepted, for return to regular stock, any drug already dispensed in

628 good faith or delivered from a pharmacy, and exposed to possible and  
629 uncontrolled contamination or substitution; (11) has accepted, for return  
630 to general inventory or regular stock, any drug sold or delivered to a  
631 patient, unless accepting such drug for return to general inventory or  
632 regular stock is otherwise permitted or required by law; (12) has split  
633 fees for professional services, including a discount or rebate, with a  
634 prescribing practitioner or an administrator or owner of a nursing home,  
635 hospital or other health care facility; [(12)] (13) has entered into an  
636 agreement with a prescribing practitioner or an administrator or owner  
637 of a nursing home, hospital or other health care facility for the  
638 compounding or dispensing of secret formula or coded prescriptions;  
639 [(13)] (14) has performed or been a party to a fraudulent or deceitful  
640 practice or transaction; [(14)] (15) has presented to the commission a  
641 diploma, license or certificate illegally or fraudulently obtained, or  
642 obtained from a college or school of pharmacy not approved by the  
643 commission; [(15)] (16) has performed incompetent or negligent work;  
644 [(16)] (17) has falsified a continuing education document submitted to  
645 the commission or department or a certificate retained in accordance  
646 with the provisions of subsection (d) of section 20-600; [(17)] (18) has  
647 permitted a person not licensed to practice pharmacy in this state to  
648 practice pharmacy in violation of section 20-605, to use a pharmacist  
649 license or pharmacy display document in violation of section 20-608, or  
650 to use words, displays or symbols in violation of section 20-609; [(18)]  
651 (19) has failed to maintain the entire pharmacy premises, its components  
652 and contents in a clean, orderly and sanitary condition; [(19)] (20) has  
653 failed to demonstrate adherence to applicable provisions of United  
654 States Pharmacopeia, Chapter 797, Pharmaceutical Compounding -  
655 Sterile Preparations, as amended from time to time; or [(20)] (21) has  
656 failed to demonstrate adherence to applicable provisions of United  
657 States Pharmacopeia, Chapter 795, Pharmaceutical Compounding -  
658 Nonsterile Preparations, as amended from time to time.

659 Sec. 6. Subsections (a) to (c), inclusive, of section 20-598a of the  
660 general statutes are repealed and the following is substituted in lieu  
661 thereof (*Effective October 1, 2024*):

662 (a) No person shall act as a pharmacy technician unless registered  
663 with, or certified with, the department, except an individual who is  
664 enrolled in an accredited pharmacy technician education program may  
665 engage in the duties of a pharmacy technician, as part of the curriculum  
666 of such program, under the direct supervision of a pharmacist who is an  
667 instructor for such program.

668 (b) The department shall [, upon authorization of the commission,]  
669 register as a pharmacy technician any person who presents evidence  
670 satisfactory to the department that such person is qualified to perform,  
671 under the [direct] supervision of a pharmacist, routine functions in the  
672 dispensing of drugs that do not require the use of professional  
673 judgment. The qualifications for registration as a pharmacy technician  
674 under this section shall be in accordance with (1) the standards of an  
675 institutional pharmacy, a care-giving institution or a correctional or  
676 juvenile training institution, in the case of employment in any such  
677 pharmacy or institution, or (2) the standards established by regulation  
678 adopted by the commissioner in accordance with the provisions of  
679 chapter 54, in the case of employment in a pharmacy. [As used in this  
680 subsection, "direct supervision" means a supervising pharmacist (A) is  
681 physically present in the area or location where the pharmacy technician  
682 is performing routine drug dispensing functions, and (B) conducts  
683 in-process and final checks on the pharmacy technician's performance.]

684 (c) The department shall [, upon authorization of the commission,]  
685 certify as a pharmacy technician any person who meets the  
686 requirements for registration as a pharmacy technician, pursuant to  
687 subsection (b) of this section, and who holds a certification from the  
688 Pharmacy Technician Certification Board or any other equivalent  
689 pharmacy technician certification program approved by the  
690 department.

691 Sec. 7. Section 20-601 of the 2024 supplement to the general statutes  
692 is repealed and the following is substituted in lieu thereof (*Effective*  
693 *October 1, 2024*):

694 The department shall collect the following nonrefundable fees:

695 (1) The fee for issuance of a pharmacist license is two hundred  
696 dollars, payable at the date of application for the license.

697 (2) The fee for renewal of a pharmacist license is the professional  
698 services fee for class A, as defined in section 33-182l. Before the  
699 commission or commissioner grants a license to an applicant who has  
700 not held a license authorized by the commission or commissioner within  
701 five years of the date of application, the applicant shall pay the fee  
702 required in subdivision (1) of this section.

703 (3) The fee for issuance of a pharmacy license is seven hundred fifty  
704 dollars.

705 (4) The fee for renewal of a pharmacy license is one hundred ninety  
706 dollars.

707 (5) The late fee for an application for renewal of a license to practice  
708 pharmacy, a pharmacy license or a permit to sell nonlegend drugs is the  
709 amount set forth in section 21a-4.

710 (6) The fee for notice of a change in officers or directors of a  
711 [corporation] business entity holding a pharmacy license is sixty dollars  
712 for each pharmacy license held. A late fee for failing to give such notice  
713 within ten days of the change is fifty dollars in addition to the fee for  
714 notice.

715 (7) The fee for filing notice of a change in name, ownership or  
716 management of a pharmacy is ninety dollars. A late fee for failing to give  
717 such notice within ten days of the change is fifty dollars in addition to  
718 the fee for notice.

719 (8) The fee for application for registration as a pharmacy intern is  
720 sixty dollars.

721 (9) The fee for application for a permit to sell nonlegend drugs is one  
722 hundred forty dollars.



723 (10) The fee for renewal of a permit to sell nonlegend drugs is one  
724 hundred dollars.

725 (11) The late fee for failing to notify the [commission] department of  
726 a change of ownership, name or location of the premises of a permit to  
727 sell nonlegend drugs within five days of the change is twenty dollars.

728 (12) The fee for issuance of a nonresident pharmacy certificate of  
729 registration is seven hundred fifty dollars.

730 (13) The fee for renewal of a nonresident pharmacy certificate of  
731 registration is one hundred ninety dollars.

732 (14) The fee for notice of a change in officers or directors of a  
733 [corporation] business entity holding a nonresident pharmacy  
734 certificate of registration is sixty dollars for each pharmacy license held.  
735 A late fee for failing to give such notice within ten days of the change is  
736 fifty dollars, in addition to the fee for notice.

737 (15) The fee for filing notice of a change in name, ownership or  
738 management of a nonresident pharmacy is ninety dollars. A late fee for  
739 failing to give such notice within ten days of the change is fifty dollars,  
740 in addition to the fee for notice.

741 (16) The fee for application for registration as a pharmacy technician  
742 is one hundred dollars.

743 (17) The fee for renewal of a registration as a pharmacy technician is  
744 fifty dollars.

745 (18) The fee for application for designation as an advanced pharmacy  
746 technician is twenty-five dollars, which fee shall be in addition to the fee  
747 required in subdivision (16) of this section.

748 (19) The fee for renewal of a designation as an advanced pharmacy  
749 technician is twenty-five dollars, which fee shall be in addition to the fee  
750 required in subdivision (17) of this section.

751 [(18)] (20) The fee for issuance of a temporary permit to practice  
752 pharmacy is two hundred dollars.

753 (21) The fee for application for registration, and renewal of a  
754 registration, as a clerk is twenty-five dollars.

755 Sec. 8. Section 20-601 of the 2024 supplement to the general statutes,  
756 as amended by section 7 of this act, is repealed and the following is  
757 substituted in lieu thereof (*Effective July 1, 2025*):

758 The department shall collect the following nonrefundable fees:

759 (1) The fee for issuance of a pharmacist license is two hundred  
760 dollars, payable at the date of application for the license.

761 (2) The fee for renewal of a pharmacist license is [the professional  
762 services fee for class A, as defined in section 33-182] one hundred five  
763 dollars. Before the commission or commissioner grants a license to an  
764 applicant who has not held a license authorized by the commission or  
765 commissioner within five years of the date of application, the applicant  
766 shall pay the fee required in subdivision (1) of this section. On or before  
767 the last day of January, April, July and October in each year, the  
768 commissioner shall transfer five dollars of each renewal fee collected  
769 pursuant to this subdivision to the pharmacy professional assistance  
770 program account established in section 20-638c.

771 (3) The fee for issuance of a pharmacy license is seven hundred fifty  
772 dollars.

773 (4) The fee for renewal of a pharmacy license is one hundred ninety  
774 dollars.

775 (5) The late fee for an application for renewal of a license to practice  
776 pharmacy, a pharmacy license or a permit to sell nonlegend drugs is the  
777 amount set forth in section 21a-4.

778 (6) The fee for notice of a change in officers or directors of a business  
779 entity holding a pharmacy license is sixty dollars for each pharmacy

780 license held. A late fee for failing to give such notice within ten days of  
781 the change is fifty dollars in addition to the fee for notice.

782 (7) The fee for filing notice of a change in name, ownership or  
783 management of a pharmacy is ninety dollars. A late fee for failing to give  
784 such notice within ten days of the change is fifty dollars in addition to  
785 the fee for notice.

786 (8) The fee for application for registration as a pharmacy intern is  
787 [sixty dollars] sixty-five dollars. On or before the last day of January,  
788 April, July and October in each year, the commissioner shall transfer  
789 five dollars of each fee collected pursuant to this subdivision to the  
790 pharmacy professional assistance program account established in  
791 section 20-638c.

792 (9) The fee for application for a permit to sell nonlegend drugs is one  
793 hundred forty dollars.

794 (10) The fee for renewal of a permit to sell nonlegend drugs is one  
795 hundred dollars.

796 (11) The late fee for failing to notify the department of a change of  
797 ownership, name or location of the premises of a permit to sell  
798 nonlegend drugs within five days of the change is twenty dollars.

799 (12) The fee for issuance of a nonresident pharmacy certificate of  
800 registration is seven hundred fifty dollars.

801 (13) The fee for renewal of a nonresident pharmacy certificate of  
802 registration is one hundred ninety dollars.

803 (14) The fee for notice of a change in officers or directors of a business  
804 entity holding a nonresident pharmacy certificate of registration is sixty  
805 dollars for each pharmacy license held. A late fee for failing to give such  
806 notice within ten days of the change is fifty dollars, in addition to the fee  
807 for notice.

808 (15) The fee for filing notice of a change in name, ownership or

809 management of a nonresident pharmacy is ninety dollars. A late fee for  
810 failing to give such notice within ten days of the change is fifty dollars,  
811 in addition to the fee for notice.

812 (16) The fee for application for registration as a pharmacy technician  
813 is one hundred dollars.

814 (17) The fee for renewal of a registration as a pharmacy technician is  
815 fifty dollars.

816 (18) The fee for application for designation as an advanced pharmacy  
817 technician is twenty-five dollars, which fee shall be in addition to the fee  
818 required in subdivision (16) of this section.

819 (19) The fee for renewal of a designation as an advanced pharmacy  
820 technician is twenty-five dollars, which fee shall be in addition to the fee  
821 required in subdivision (17) of this section.

822 (20) The fee for issuance of a temporary permit to practice pharmacy  
823 is two hundred dollars.

824 (21) The fee for application for registration, and renewal of a  
825 registration, as a clerk is twenty-five dollars.

826 Sec. 9. Section 20-633 of the 2024 supplement to the general statutes  
827 is repealed and the following is substituted in lieu thereof (*Effective*  
828 *October 1, 2024*):

829 (a) (1) Any person licensed as a pharmacist under part II of this  
830 chapter may order, prescribe and administer:

831 (A) Any vaccine, approved or authorized by the United States Food  
832 and Drug Administration that is listed on the National Centers for  
833 Disease Control and Prevention's [Adult Immunization Schedule] age-  
834 appropriate immunization schedule, to any patient who is: (i) Eighteen  
835 years of age or older; or (ii) at least twelve years of age but younger than  
836 eighteen years of age with (I) the consent of such patient's parent, legal  
837 guardian or other person having legal custody of such patient, or (II)

838 proof that such patient is an emancipated minor; [.]

839 (B) Any vaccine not included on the National Centers for Disease  
840 Control and Prevention's Adult Immunization Schedule to any patient  
841 who is eighteen years of age or older, provided the vaccine  
842 administration instructions for such vaccine are available on the  
843 National Centers for Disease Control and Prevention's Internet web site;  
844 and

845 (C) Any vaccine pursuant to a verbal or written prescription of a  
846 prescribing practitioner for a specific patient.

847 (2) A pharmacist shall make a reasonable effort to review a patient's  
848 vaccination history to prevent any inappropriate use of a requested  
849 vaccine.

850 (3) All vaccines administered pursuant to this section shall be  
851 administered in accordance with the: (A) Vaccine manufacturer's  
852 package insert or the orders of a prescribing practitioner; and (B)  
853 regulations adopted pursuant to subsection (d) of this section.

854 (4) A pharmacist may delegate to an advanced pharmacy technician  
855 the pharmacist's authority to administer a vaccine described in  
856 subparagraph (A) of subdivision (1) of this subsection to a patient  
857 described in said subparagraph, provided the advanced pharmacy  
858 technician administers the vaccine: (A) Under the direct supervision of  
859 such pharmacist; and (B) in accordance with the provisions of this  
860 section and the regulations adopted pursuant to subsection (d) of this  
861 section.

862 (b) A pharmacist who has completed the training required in  
863 regulations adopted pursuant to subsection (d) of this section may  
864 administer an epinephrine cartridge injector, as defined in section 19a-  
865 909, to a patient whom the pharmacist reasonably believes, based on  
866 such pharmacist's knowledge and training, is experiencing anaphylaxis,  
867 regardless of whether such patient has a prescription for an epinephrine  
868 cartridge injector. Such pharmacist, or such pharmacist's designee, shall

869 call the 9-1-1 emergency telephone number either before or immediately  
870 after such pharmacist administers the epinephrine cartridge injector to  
871 such patient. Such pharmacist shall document the date, time and  
872 circumstances in which such pharmacist administered such epinephrine  
873 cartridge injector, and maintain such documentation for at least three  
874 years.

875 (c) (1) A certified and registered pharmacy technician may administer  
876 a vaccine to a patient at a pharmacy if: (A) The managing pharmacist of  
877 such pharmacy is authorized to administer vaccines under this section;  
878 and (B) such pharmacy technician (i) has successfully completed a  
879 course of hands-on training, certified by the American Council for  
880 Pharmacy Education, concerning the administration of vaccines, (ii) has  
881 been trained at such pharmacy regarding the process for administering  
882 vaccines to patients at such pharmacy, (iii) successfully completes at  
883 least one hour of annual continuing education concerning  
884 immunization, (iv) has been evaluated by the managing pharmacist of  
885 such pharmacy, and (v) administers such vaccine at the direction of the  
886 pharmacist on duty at such pharmacy.

887 (2) During the period beginning on September first and ending on  
888 March thirty-first of the succeeding calendar year, a certified and  
889 registered pharmacy technician shall not count toward the pharmacist-  
890 to-technician ratio set forth in section 20-576-33 of the regulations of  
891 Connecticut state agencies if such pharmacy technician: (A) Is  
892 authorized to administer vaccines under this section; and (B) exclusively  
893 performs duties related to the administration of vaccines during such  
894 period.

895 (d) (1) The Commissioner of Consumer Protection, in consultation  
896 with the Commissioner of Public Health and the Commission of  
897 Pharmacy, shall adopt regulations, in accordance with the provisions of  
898 chapter 54, to implement the provisions of this section. Such regulations  
899 shall: [(1)] (A) Require any pharmacist who administers a vaccine  
900 pursuant to this section to successfully complete an immunization  
901 training program for pharmacists; [(2)] (B) define the basic requirements

902 of such training program, which shall include training and instruction  
903 in pre-administration education and screening, vaccine storage and  
904 handling, subcutaneous and intramuscular injections, recordkeeping,  
905 vaccine safety, cardiopulmonary resuscitation, basic cardiac life support  
906 and adverse event reporting; [(3)] (C) identify qualifying training  
907 programs, which are accredited by the National Centers for Disease  
908 Control Prevention, the Accreditation Council for Pharmacy Education  
909 or another appropriate national accrediting body; and [(4)] (D) establish  
910 a system of control and reporting.

911 (2) The Commissioner of Consumer Protection may amend the  
912 regulations adopted pursuant to subdivision (1) of this subsection, in  
913 accordance with the provisions of chapter 54, to: (A) Establish additional  
914 requirements concerning delegations by pharmacists to advanced  
915 pharmacy technicians under this section; and (B) the administration of  
916 vaccines by advanced pharmacy technicians under this section.

917 Sec. 10. Section 20-633f of the 2024 supplement to the general statutes  
918 is repealed and the following is substituted in lieu thereof (*Effective*  
919 *October 1, 2024*):

920 (a) For the purposes of this section:

921 (1) "COVID-19" means the respiratory disease designated by the  
922 World Health Organization on February 11, 2020, as coronavirus 2019,  
923 and any related mutation thereof recognized by said organization;

924 (2) "COVID-19-related test" means any laboratory test, or series of  
925 laboratory tests, for any virus, antibody, antigen or etiologic agent  
926 thought to cause, or indicate the presence of, COVID-19;

927 (3) "HIV-related prophylaxis" means any drug approved by the  
928 federal Food and Drug Administration or any successor agency as a pre-  
929 exposure or post-exposure prophylaxis for the human  
930 immunodeficiency virus;

931 (4) "HIV-related test" has the same meaning as provided in section

932 19a-7o; and

933 (5) "Influenza-related test" means any laboratory test, or series of  
934 laboratory tests, for any virus, antibody, antigen or etiologic agent  
935 thought to cause, or indicate the presence of, influenza disease.

936 (b) (1) Any pharmacist licensed under this chapter may order, and  
937 administer to a patient, a COVID-19-related test or influenza-related test  
938 if: (A) Such pharmacist (i) is employed by a pharmacy that has  
939 submitted to the Department of Public Health a complete clinical  
940 laboratory improvement amendment application for certification for the  
941 COVID-19-related test or influenza-related test and the Department of  
942 Public Health has approved such application, and (ii) has completed any  
943 training required by the Department of Consumer Protection; and (B)  
944 the patient is (i) eighteen years of age or older, or (ii) at least twelve years  
945 of age but younger than eighteen years of age with (I) the consent of  
946 such patient's parent, legal guardian or other person having legal  
947 custody of such patient, or (II) proof that such patient is an emancipated  
948 minor.

949 (2) Any pharmacist licensed under this chapter may order, and  
950 administer to a patient, a COVID-19-related test or influenza-related test  
951 if: (A) Such pharmacist is employed by a hospital; and (B) the patient is  
952 (i) eighteen years of age or older, or (ii) at least twelve years of age but  
953 younger than eighteen years of age with (I) the consent of such patient's  
954 parent, legal guardian or other person having legal custody of such  
955 patient, or (II) proof that such patient is an emancipated minor.

956 (3) Any pharmacist licensed under this chapter may delegate to an  
957 advanced pharmacy technician the pharmacist's authority to administer  
958 to a patient a COVID-19-related test or influenza-related test under this  
959 subsection if: (A) The advanced pharmacy technician has completed any  
960 training required by the Department of Consumer Protection  
961 concerning the proper administration of the COVID-19-related test or  
962 influenza-related test; and (B) the advanced pharmacy technician  
963 administers the COVID-19-related test or influenza-related test (i) under



964 the direct supervision of such pharmacist, and (ii) in accordance with  
965 the provisions of this section and the regulations adopted pursuant to  
966 subsection (g) of this section.

967 (c) (1) On or after the adoption of regulations pursuant to subsection  
968 (g) of this section, any pharmacist licensed under this chapter may  
969 order, and administer to a patient, an HIV-related test if: (A) Such  
970 pharmacist (i) is employed by a pharmacy that has submitted to the  
971 Department of Public Health a complete clinical laboratory  
972 improvement amendment application for certification for the HIV-  
973 related test and the Department of Public Health has approved such  
974 application, and (ii) has completed the training required under  
975 regulations adopted pursuant to subsection (g) of this section; and (B)  
976 the patient is (i) eighteen years of age or older, or (ii) at least twelve years  
977 of age but younger than eighteen years of age with (I) the consent of  
978 such patient's parent, legal guardian or other person having legal  
979 custody of such patient, or (II) proof that such patient is an emancipated  
980 minor.

981 (2) On or after the adoption of regulations pursuant to subsection (g)  
982 of this section, any pharmacist licensed under this chapter may order,  
983 and administer to a patient, an HIV-related test if: (A) Such pharmacist  
984 is employed by a hospital; and (B) the patient is (i) eighteen years of age  
985 or older, or (ii) at least twelve years of age but younger than eighteen  
986 years of age and such pharmacist has obtained (I) the consent of such  
987 patient's parent, legal guardian or other person having legal custody of  
988 such patient, or (II) proof that such patient is an emancipated minor.

989 (3) Any pharmacist licensed under this chapter may delegate to an  
990 advanced pharmacy technician the pharmacist's authority to administer  
991 to a patient an HIV-related test under this subsection and the  
992 regulations adopted pursuant to subsection (g) of this section if: (A) The  
993 advanced pharmacy technician has completed any training required by  
994 the Department of Consumer Protection concerning the proper  
995 administration of the HIV-related test; and (B) the advanced pharmacy  
996 technician administers the HIV-related test (i) under the direct

997 supervision of such pharmacist, and (ii) in accordance with the  
998 provisions of this section and the regulations adopted pursuant to  
999 subsection (g) of this section.

1000 (d) (1) If a pharmacist orders and administers, or if a pharmacist  
1001 orders and an advanced pharmacy technician working under the  
1002 pharmacist's direct supervision administers, a COVID-19-related test or  
1003 influenza-related test under subsection (b) of this section, or an HIV-  
1004 related test under subsection (c) of this section, the pharmacist shall: [(1)]  
1005 (A) Provide the results of such test to [(A)] (i) the patient, in writing,  
1006 [(B)] (ii) the patient's primary care provider, if the patient identifies any  
1007 such primary care provider, and [(C)] (iii) the Commissioner of  
1008 Consumer Protection or said commissioner's designee, upon request by  
1009 said commissioner or such designee; [(2)] (B) report the results of such  
1010 test to the director of health of the town, city or borough in which such  
1011 case resides and to the Department of Public Health in the manner set  
1012 forth in section 19a-215 and applicable regulations; and [(3)] (C)  
1013 maintain a record of the results of such test for three years.

1014 (2) No pharmacist shall delegate to an advanced pharmacy technician  
1015 the pharmacist's duty to provide to the patient the results of: (A) A  
1016 COVID-19-related test or influenza-related test ordered and  
1017 administered under subsection (b) of this section; or (B) an HIV-related  
1018 test ordered and administered under subsection (c) of this section.

1019 (e) (1) If a pharmacist orders and administers, or if a pharmacist  
1020 orders and an advanced pharmacy technician working under the  
1021 pharmacist's direct supervision administers, an HIV-related test under  
1022 subsection (c) of this section and the result of such test is negative, the  
1023 pharmacist may prescribe and dispense to the patient any HIV-related  
1024 prophylaxis according to the manufacturer's package insert, provided:  
1025 (A) Such pharmacist has completed the training required under the  
1026 regulations adopted pursuant to subsection (g) of this section; (B) such  
1027 patient satisfies the criteria established in such package insert; and (C)  
1028 such HIV-related prophylaxis is prescribed and dispensed in  
1029 accordance with all applicable requirements established in (i) this

1030 section, (ii) this chapter, or (iii) any regulations adopted pursuant to  
1031 subsection (g) of this section or this chapter.

1032 (2) If a pharmacist prescribes any HIV-related prophylaxis under  
1033 subdivision (1) of this subsection, the pharmacist shall provide to the  
1034 Commissioner of Consumer Protection or the commissioner's designee,  
1035 upon request by said commissioner or such designee: (A) A copy of the  
1036 results of the HIV-related test described in subdivision (1) of this  
1037 subsection; (B) prescription information maintained pursuant to this  
1038 chapter; and (C) any other documentation the commissioner may  
1039 require in regulations adopted pursuant to subsection (g) of this section.

1040 (f) Notwithstanding the provisions of section 1-210, all information a  
1041 pharmacist submits to the Department of Consumer Protection  
1042 pursuant to this section, or any regulation adopted pursuant to  
1043 subsection (g) of this section, shall be confidential. The department shall  
1044 use such information to perform the department's duties concerning  
1045 pharmacy, to ensure compliance with and enforce provisions of the  
1046 general statutes and regulations of Connecticut state agencies  
1047 concerning pharmacy and for no other purpose. If the department  
1048 brings an enforcement action and uses any such information as part of  
1049 such action, the department may disclose such information to the parties  
1050 to such action only if such disclosure is required by applicable law. No  
1051 such party shall further disclose such information except to a tribunal,  
1052 the Commission of Pharmacy, an administrative agency or a court with  
1053 jurisdiction over such action. Such tribunal, commission, agency or  
1054 court shall ensure that such information is subject to a qualified  
1055 protective order, as defined in 45 CFR 164.512(e), as amended from time  
1056 to time.

1057 (g) (1) The Commissioner of Consumer Protection, in consultation  
1058 with the Commissioner of Public Health, the Commission of Pharmacy,  
1059 a state-wide professional society representing the interests of physicians  
1060 practicing medicine in this state and a state-wide organization  
1061 representing the interests of health care professionals and scientists  
1062 specializing in the control and prevention of infectious diseases, shall

1063 adopt regulations, in accordance with the provisions of chapter 54, to  
1064 implement the provisions of this section. Such regulations shall, at a  
1065 minimum: [(1)] (A) Ensure compliance with all applicable guidance  
1066 issued by the federal Centers for Disease Control and Prevention; [(2)]  
1067 (B) ensure that each HIV-related prophylaxis prescribed and dispensed  
1068 under subsection (e) of this section is prescribed and dispensed in  
1069 accordance with the approval the federal Food and Drug  
1070 Administration has granted for such HIV-related prophylaxis; [(3)] (C)  
1071 establish permissible routes of administration; [(4)] (D) establish  
1072 prescription duration limits not to exceed [(A)] (i) sixty days for any pre-  
1073 exposure HIV-related prophylaxis, or [(B)] (ii) thirty days for any post-  
1074 exposure HIV-related prophylaxis; [(5)] (E) specify [(A)] (i) how  
1075 frequently a pharmacist shall provide treatment to a patient under this  
1076 section, [(B)] (ii) when a pharmacist providing treatment to a patient  
1077 under this section shall refer such patient to such patient's primary care  
1078 provider or any other health care provider identified by such patient,  
1079 and [(C)] (iii) the circumstances in which a pharmacist shall recommend  
1080 that a patient undergo screenings for sexually transmitted infections  
1081 other than the human immunodeficiency virus; [(6)] (F) establish  
1082 requirements concerning private areas for consultations between  
1083 pharmacists and patients; [(7)] (G) establish training requirements  
1084 concerning [(A)] (i) methods to obtain a patient's complete sexual  
1085 history, [(B)] (ii) delivering a positive HIV-related test result to a patient,  
1086 [(C)] (iii) referring a patient who has tested positive for the human  
1087 immunodeficiency virus to the services that are available to such  
1088 patient, and [(D)] (iv) using HIV-related prophylaxes for patients who  
1089 have tested negative for the human immunodeficiency virus; [(8)] (H)  
1090 identify qualifying training programs, which are accredited by the  
1091 National Centers for Disease Control and Prevention, the Accreditation  
1092 Council for Pharmacy Education or another appropriate national  
1093 accrediting body; and [(9)] (I) establish a system of control and  
1094 reporting.

1095 (2) The Commissioner of Consumer Protection may amend the  
1096 regulations adopted pursuant to subdivision (1) of this subsection, in

1097 accordance with the provisions of chapter 54, to: (A) Establish additional  
1098 requirements concerning delegations by pharmacists to advanced  
1099 pharmacy technicians under this section; and (B) the administration of  
1100 COVID-19-related tests, influenza-related tests and HIV-related tests by  
1101 advanced pharmacy technicians under this section.

1102 Sec. 11. (*Effective from passage*) (a) There is established a task force to  
1103 study the impact of unannounced retail pharmacy closures. Such study  
1104 shall include, but need not be limited to, an examination of any available  
1105 means of ensuring that patients are able to maintain access to their  
1106 prescriptions in the event of an unannounced retail pharmacy closure.

1107 (b) The task force shall consist of the following members:

1108 (1) Two appointed by the speaker of the House of Representatives;

1109 (2) Two appointed by the president pro tempore of the Senate;

1110 (3) One appointed by the majority leader of the House of  
1111 Representatives;

1112 (4) One appointed by the majority leader of the Senate;

1113 (5) One appointed by the minority leader of the House of  
1114 Representatives;

1115 (6) One appointed by the minority leader of the Senate;

1116 (7) The Commissioner of Consumer Protection, or the commissioner's  
1117 designee; and

1118 (8) Two persons appointed by the Governor.

1119 (c) Any member of the task force appointed under subdivision (1),  
1120 (2), (3), (4), (5) or (6) of subsection (b) of this section may be a member  
1121 of the General Assembly.

1122 (d) All initial appointments to the task force shall be made not later  
1123 than thirty days after the effective date of this section. Any vacancy shall

1124 be filled by the appointing authority.

1125 (e) The speaker of the House of Representatives and the president pro  
 1126 tempore of the Senate shall select the chairpersons of the task force from  
 1127 among the members of the task force. Such chairpersons shall schedule  
 1128 the first meeting of the task force, which shall be held not later than sixty  
 1129 days after the effective date of this section.

1130 (f) The administrative staff of the joint standing committee of the  
 1131 General Assembly having cognizance of matters relating to consumer  
 1132 protection shall serve as administrative staff of the task force.

1133 (g) Not later than January 1, 2025, the task force shall submit a report  
 1134 on its findings and recommendations to the joint standing committee of  
 1135 the General Assembly having cognizance of matters relating to  
 1136 consumer protection, in accordance with the provisions of section 11-4a  
 1137 of the general statutes. The task force shall terminate on the date that it  
 1138 submits such report or January 1, 2025, whichever is later.

1139 Sec. 12. Section 259 of public act 23-204 is repealed. (*Effective October*  
 1140 *1, 2024*)"

This act shall take effect as follows and shall amend the following sections:		
Section 1	<i>October 1, 2024</i>	20-571
Sec. 2	<i>October 1, 2024</i>	New section
Sec. 3	<i>October 1, 2024</i>	New section
Sec. 4	<i>October 1, 2024</i>	New section
Sec. 5	<i>October 1, 2024</i>	20-579(a)
Sec. 6	<i>October 1, 2024</i>	20-598a(a) to (c)
Sec. 7	<i>October 1, 2024</i>	20-601
Sec. 8	<i>July 1, 2025</i>	20-601
Sec. 9	<i>October 1, 2024</i>	20-633
Sec. 10	<i>October 1, 2024</i>	20-633f
Sec. 11	<i>from passage</i>	New section
Sec. 12	<i>October 1, 2024</i>	Repealer section